Hola,
Are you new here?

BreathForDx

financed

Establishing Exhaled Breath Aerosol (XBA) sampling for diagnosis and screening o...

Establishing Exhaled Breath Aerosol (XBA) sampling for diagnosis and screening of respiratory infections Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of €s in economic losses. Despite the importance of early detection for individual health and pande... see more

31/12/2026

UKHD

2M€

Project Budget: 2M€

Project leader

UNIVERSITATSKLINIKUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 6 Participantes

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2023-10-14

HORIZON-HLTH-2022-DISEASE-07-02: Pandemic preparedness ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

UKHD

1.08M€ | Leader

AVELO AG

N.D. | participant

TAT

227.13K€ | participant

OSR

485.56K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 38 months Date Start: 2023-10-14
End date: 2026-12-31

Project leader

UNIVERSITATSKLINIKUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 2M€

participation deadline Sin fecha límite de participación.

Project description Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of €s in economic losses. Despite the importance of early detection for individual health and pandemic control, flawed sampling methods for respiratory infections limit the impact of highly-sensitive molecular diagnostics. BreathForDx’s overall goal is to tackle this problem by establishing exhaled breath aerosol (XBA) as a novel, evidence-based sample for respiratory infections in three use cases: diagnosis, screening, and antimicrobial resistance, using tuberculosis (TB) as a model infection. The project will leverage innovation in bioaerosol and material science, as well as the multidisciplinary (including academia, industry and NGOs) consortium’s track record of delivering transformative diagnostic innovation. More specifically, we will optimise an innovative, easy-to-use, scalable XBA sampling device, and compare it to a face mask sampling device coupled with rapid molecular detection in three clinical studies. We will evaluate the XBA sampling efficiency of these devices using the Respiratory Aerosol Sampling Chamber as a benchmark. Next, we will assess performance of the devices for diagnosis of TB and drug-resistance among symptomatic patients in a high burden EU country. In parallel, we will assess the feasibility of multiplexing XBA samples for multiple respiratory pathogens (i.e., TB, influenza, SARS-CoV-2) in a screening use case. Accuracy and feasibility data will be complemented by data on acceptability and usability, as well as cost-effectiveness and impact modelling to inform the implementation potential of the novel devices across different use cases. We envision a world in which a single breath sample, coupled with point-of-care molecular diagnostics, enables accessible and accurate pathogen and resistance detection of highly transmissible respiratory infections, thereby improving both individual and public health.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers